Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.
Amyloid Neuropathies, Familial
/ complications
Amyloidosis
/ complications
Aortic Valve Stenosis
/ complications
Cardiomyopathies
/ complications
Cardiomyopathy, Hypertrophic
/ complications
Carpal Tunnel Syndrome
/ complications
Heart Failure
/ complications
Humans
Hypertrophy, Left Ventricular
/ complications
Radionuclide Imaging
Stroke Volume
aortic stenosis
carpal tunnel syndrome
heart failure
left ventricular hypertrophy
transthyretin cardiac amyloidosis
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
11
08
2021
received:
10
06
2021
accepted:
12
08
2021
pubmed:
15
8
2021
medline:
17
3
2022
entrez:
14
8
2021
Statut:
ppublish
Résumé
Transthyretin-related cardiac amyloidosis (TTR-CA) is thought to be particularly common in specific at-risk conditions, including aortic stenosis (AS), heart failure with preserved ejection fraction (HFpEF), carpal tunnel syndrome (CTS) and left ventricular hypertrophy or hypertrophic cardiomyopathy (LVH/HCM). We performed a systematic revision of the literature, including only prospective studies performing TTR-CA screening with bone scintigraphy in the above-mentioned conditions. Assessment of other forms of CA was also evaluated. For selected items, pooled estimates of proportions or means were obtained using a meta-analytic approach. Nine studies (3 AS, 2 HFpEF, 2 CTS and 2 LVH/HCM) accounting for 1375 screened patients were included. One hundred fifty-six (11.3%) TTR-CA patients were identified (11.4% in AS, 14.8% in HFpEF, 2.6% in CTS and 12.9% in LVH/HCM). Exclusion of other forms of CA and use of genetic testing was overall puzzled. Age at TTR-CA recognition was significantly older than that of the overall screened population in AS (86 vs. 83 years, p = .04), LVH/HCM (75 vs. 63, p < .01) and CTS (82 vs. 71), but not in HFpEF (83 vs. 79, p = .35). In terms of comorbidities, hypertension, diabetes and atrial fibrillation were highly prevalent in TTR-CA-diagnosed patients, as well as in those with an implanted pacemaker. Screening with bone scintigraphy found an 11-15% TTR-CA prevalence in patients with AS, HFpEF and LVH/HCM. AS and HFpEF patients were typically older than 80 years at TTR-CA diagnosis and frequently accompanied by comorbidities. Several studies showed limitations in the application of recommended TTR-CA diagnostic algorithm, which should be addressed in future prospective studies.
Sections du résumé
BACKGROUND
BACKGROUND
Transthyretin-related cardiac amyloidosis (TTR-CA) is thought to be particularly common in specific at-risk conditions, including aortic stenosis (AS), heart failure with preserved ejection fraction (HFpEF), carpal tunnel syndrome (CTS) and left ventricular hypertrophy or hypertrophic cardiomyopathy (LVH/HCM).
METHODS
METHODS
We performed a systematic revision of the literature, including only prospective studies performing TTR-CA screening with bone scintigraphy in the above-mentioned conditions. Assessment of other forms of CA was also evaluated. For selected items, pooled estimates of proportions or means were obtained using a meta-analytic approach.
RESULTS
RESULTS
Nine studies (3 AS, 2 HFpEF, 2 CTS and 2 LVH/HCM) accounting for 1375 screened patients were included. One hundred fifty-six (11.3%) TTR-CA patients were identified (11.4% in AS, 14.8% in HFpEF, 2.6% in CTS and 12.9% in LVH/HCM). Exclusion of other forms of CA and use of genetic testing was overall puzzled. Age at TTR-CA recognition was significantly older than that of the overall screened population in AS (86 vs. 83 years, p = .04), LVH/HCM (75 vs. 63, p < .01) and CTS (82 vs. 71), but not in HFpEF (83 vs. 79, p = .35). In terms of comorbidities, hypertension, diabetes and atrial fibrillation were highly prevalent in TTR-CA-diagnosed patients, as well as in those with an implanted pacemaker.
CONCLUSIONS
CONCLUSIONS
Screening with bone scintigraphy found an 11-15% TTR-CA prevalence in patients with AS, HFpEF and LVH/HCM. AS and HFpEF patients were typically older than 80 years at TTR-CA diagnosis and frequently accompanied by comorbidities. Several studies showed limitations in the application of recommended TTR-CA diagnostic algorithm, which should be addressed in future prospective studies.
Identifiants
pubmed: 34390490
doi: 10.1111/eci.13665
pmc: PMC9286629
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13665Informations de copyright
© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
JACC Heart Fail. 2021 Mar;9(3):169-178
pubmed: 33549560
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Eur J Heart Fail. 2020 Oct;22(10):1852-1862
pubmed: 32078212
JACC Cardiovasc Imaging. 2021 Jan;14(1):293-295
pubmed: 32828772
Eur Heart J. 2017 Jun 21;38(24):1895-1904
pubmed: 28329248
Eur J Heart Fail. 2020 Sep;22(9):1740-1741
pubmed: 32243647
J Cardiovasc Transl Res. 2019 Dec;12(6):507-513
pubmed: 31214980
Int J Cardiovasc Imaging. 2016 Sep;32(9):1403-1413
pubmed: 27240600
Circulation. 2017 Apr 4;135(14):1357-1377
pubmed: 28373528
Cancer. 1992 Sep 1;70(5 Suppl):1252-8
pubmed: 1511372
Int J Cardiol. 2020 Feb 1;300:191-195
pubmed: 31371117
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Eur J Heart Fail. 2021 Feb;23(2):259-263
pubmed: 33190343
Eur J Heart Fail. 2021 Apr;23(4):512-526
pubmed: 33826207
Eur J Heart Fail. 2018 Mar;20(3):504-510
pubmed: 29193462
JACC Cardiovasc Imaging. 2020 Jun;13(6):1314-1321
pubmed: 31864976
Circ Heart Fail. 2019 Sep;12(9):e006075
pubmed: 31480867
Int J Cardiol. 2021 Jul 15;335:123-127
pubmed: 33865873
JACC Heart Fail. 2019 Aug;7(8):709-716
pubmed: 31302046
Amyloid. 2017 Jun;24(2):101-109
pubmed: 28553897
Eur Heart J. 2020 Apr 7;41(14):1439-1447
pubmed: 31950987
Eur Heart J. 2020 Aug 1;41(29):2759-2767
pubmed: 32267922
Eur J Clin Invest. 2021 Dec;51(12):e13665
pubmed: 34390490
Eur J Clin Invest. 2010 Jan;40(1):35-53
pubmed: 20055895
ESC Heart Fail. 2021 Aug;8(4):3369-3374
pubmed: 33988312
Int J Cardiol. 2021 Apr 15;329:144-147
pubmed: 33358831
Eur J Heart Fail. 2018 Sep;20(9):1257-1266
pubmed: 29917301
Circulation. 2020 Apr 14;141(15):1214-1224
pubmed: 32078382
JACC Heart Fail. 2017 Aug;5(8):617
pubmed: 28774400
JACC Cardiovasc Imaging. 2021 Jun;14(6):1221-1231
pubmed: 33221204
Eur J Heart Fail. 2021 Feb;23(2):250-258
pubmed: 32729170
Eur Heart J. 2013 May;34(19):1448-58
pubmed: 23211230
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929